story of the week
Eribulin Mesylate as Third- or Subsequent-Line Chemotherapy in Elderly Patients With Locally Recurrent or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eribulin Mesylate as Third or Subsequent Line Chemotherapy in Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE
Oncologist 2018 Nov 09;[EPub Ahead of Print], S Leo, E Arnoldi, L Repetto, Z Coccorullo, S Cinieri, M Fedele, M Cazzaniga, V Lorusso, A Latorre, G Campanella, M Ciccarese, C Accettura, S Pisconti, A Rinaldi, C Brunetti, M Raffaele, L Coltelli, S Spazzapan, L Fratino, L Petrucelli, L BiganzoliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.